Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
FLUDARABINE PHOSPHATE
HOSPIRA UK Ltd
FLUDARABINE PHOSPHATE
50 Milligram
Pdr for Soln Inj/Inf
Product subject to prescription which may not be renewed (A)
Authorised
0000-00-00
1 PACKAGE LEAFLET: INFORMATION FOR THE USER FLUDARABINE PHOSPHATE 50 MG POWDER FOR SOLUTION FOR INJECTION OR INFUSION Fludarabine phosphate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their sign of illness are the same as yours. - If you get any side effects talk to your doctor or pharmacist.This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Fludarabine Phosphate Powder for Solution for Injection or Infusion is and what it is used for 2. What you need to know before you are given Fludarabine Phosphate Powder for Solution for Injection or Infusion 3. How to use Fludarabine Phosphate Powder for Solution for Injection or Infusion 4. Possible side effects 5. How to store Fludarabine Phosphate Powder for Solution for Injection or Infusion 6. Contents of the pack and other information 1. WHAT FLUDARABINE PHOSPHATE POWDER FOR SOLUTION FOR INJECTION OR INFUSION IS AND WHAT IT IS USED FOR Fludarabine phosphate is an anti-cancer medicine. Fludarabine phosphate is used in the treatment of B-cell chronic lymphocytic leukaemia (B-CLL) in patients who have a sufficient amount of healthy blood cells in their bone marrow. First treatment for chronic lymphocytic leukaemia with fludarabine phosphate should only be started in patients with advanced disease having disease related symptoms or evidence of disease progression. Fludarabine phosphate works by stopping the growth of new cancer cells. All cells of the body produce Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fludarabine Phosphate 50 mg Powder for Solution for Injection or Infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 50 mg of fludarabine phosphate. 1 ml of reconstituted solutions contains 25 mg of fludarabine phosphate. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Powder for solution for injection or infusion. A white plug. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of B-cell chronic lymphocytic leukaemia (CLL) in patients with sufficient bone marrow reserves. First line treatment with Fludarabine Phosphate 50 mg Powder for Solution for Injection or Infusion should only be initiated in patients with advanced disease, Rai stages III/IV (binet stage C), or Rai stages I/II (Binet stage A/B) where the patient has disease related symptoms or evidence of progressive disease. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Fludarabine Phosphate Powder for Solution for Injection or Infusion should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy. Method of administration Fludarabine Phosphate Powder for Solution for Injection or Infusion is for intravenous use only. No cases have been reported in which paravenously administered fludarabine phosphate led to severe local adverse reactions. However, paravenous administration must be avoided. ADULTS The recommended dose of fludarabine phosphate is 25 mg/m 2 body surface area given daily for 5 consecutive days, every 28 days by the intravenous route. Each vial is to be made up in 2 ml water for injection. Each ml of the resulting solution will contain 25 mg fludarabine phosphate. The required dose (calculated on the basis of the patient’s body Read the complete document